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The surgical treatment of acute heart failure is limited to cases of pressure or volume overload. Acute valvular
•• regurgitation due to active endocarditis or to prosthetic dysfunction is a classic example of failure which can be
cured by restoring valvular competence. Acute pressure load is mostly caused by prosthetic dysfunction or
pulmonary embolism; therapy is aimed at removal of the causative agent. Coronary heart disease can cause heart
failure by volume overload: acute mitral incompetence or ventricular septal defect lend themselves to surgical
correction. In the surgical treatment of acute heart failure maximal attention is devoted to optimal timing of
surgery, anesthetic management and postoperative care. Careful attention to the function of the right and left
ventricle and combination of catecholamines, afterload reducing agents and volume loading together with
respirator support have considerably improved the surgical results. Acute pump failure due to coronary
_^ insufficiency and infarction is less amenable to surgical treatment, with rare exceptions of emergencies during
coronary angiography and percutaneous dilatation. The intra-aortic balloon pump is the only method of
v mechanical circulatory assistance which has reached widespread clinical acceptance. The best results are achieved
in conjunction with surgery: either as cardiac support in inherently reversible postoperative heart failure or as the
means of circulatory stabilization prior to surgery. Ventricular assist devices are still in the experimental stage:
their use has been sharply curtailed by the virtual disappearance of the postoperative low output syndrome. In
selected cases of end-stage cardiomyopathy cardiac transplantation is nowadays performed with acceptable
-
r
 survival (70% at one year after surgery). Both orthotopic and heterotopic transplantation (transplanted heart in
^ parallel with the natural one) give comparable results, but the procedure is still very restricted due to the lack of
donors, multiple contraindications and lack of suitable heart preservation techniques.
Heart failure is defined as inability of the heart to Table 1 Surgical treatment of acute heart failure
provide adequate cardiac output to satisfy metabolic
   s  etabolc
demands of the organism'". Therefore heart failure is ' Restoring valvular competence:
primarily a defect of the contractile pumping acute endocarditis
v J
 . , _ • • / . prosthetic dysfunction
component and lends itself only rarely to surgical papillary muscle dysfunction
relief. Nevertheless, several conditions causing acute aortic dissection
and chronic heart failure are nowadays amenable to 2- Eliminating volume overload:
surgical treatment and even total heart replacement postinfarction VSD
, . ... ruptured sinus valsalvae aneurysm
has become possible.
 3 E | i m i n a t i n g p r e s s u r e o v e r l o J
prosthetic dysfunction
pulmonary embolism
4. Emergency revascularization.
Methods angioplasty accident
, , . . . , , iatrogenic coronary dissection
Surgical treatment in acute heart failure is possible
 a c u t e lnfarction (?)
when the disease has been caused by a sudden volume
or pressure load of the heart—mostly of the left
ventricle. Surgical therapy is strictly aimed at the satisfactory in several complications of valvular and
removal of the causative agent which led to the coronary heart disease (Table 1).
development of the heart failure. The results are very Closure of postinfarction ventricular septal defect
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(VSD) has become a standard surgical procedure
with acceptable risk'21. Utilization of large patches,
approach to the ventricular septal defect through the
infarcted zone of the left ventricle and simultaneous
coronary revascularization have enabled survival of a
large proportion of patients with otherwise extremely
limited life expectancy. Heart failure with a similar
pathophysiological mechanism is encountered in
acute mitral insufficiency caused by papillary muscle
rupture in acute infarction; again the surgical
treatment with replacement or—rarely—with repair
of the mitral valve, combined with revascularization
of the myocardium, greatly improves the otherwise
dismal prognosis in this group'341.
Marked left ventricular failure is sometimes
encountered in sudden aortic or—more rarely—mitral
valve incompetence in acute endocarditis. The
previous policy of antibiotic treatment followed by
valve replacement after sterilization of the infected
valve has been completely replaced by active surgical
management of the diseased valve'3'6'. In patients
with left ventricular failure, peripheral emboli or
infection not readily responding to treatment with
antibiotics, valvular replacement is performed early,
followed by a prolonged (3-6 weeks) course of
antibiotic treatment. Both mechanical and biopros-
thetic valves can be used for valve replacement; local
complications of the infection (annular abscesses,
septal perforation and aneurysms of the sinus of
Valsalva) are dealt with during valvular replacement.
Acute pressure overload of the left ventricle rarely
requires surgical treatment: in isolated cases of aortic
prosthesis immobilization by thrombus or tissue
ingrowth urgent surgical treatment represents the
only therapeutic modality. Both replacement of the
valve or careful removal of the thrombotic material
are possible'7 ~9).
False ventricular aneurysm is a rare complication of
acute myocardial infarction"01 requiring prompt
surgery"" because of the large volume of the
aneurysm, its potential for rupture and compression
of the surrounding structures is great. Myocardial
failure disappears almost immediately after resection
of the false aneurysm, because the infarction is
usually small. Acute coronary insufficiency is followed
by heart failure when a large area of left ventricular
myocardium—-more than 40%'4)—is in jeopardy.
Acute revascularization of the ischemic myocardium
is successful only in rare circumstances, when the
acute ischemia occurs under hospital conditions: in
accidents of coronary angioplasty"21, and dissection
or acute coronary obstructions during cardiac
catheterization. The policy of acute revascularization
of all myocardial infarctions has been pursued only in
a few centers" J 1 4 ' ; the lack of randomized studies
makes an exact appraisal of this aggressive treatment
impossible. The ischemic tolerance of a normo-
thermic. ejecting heart is measured in minutes"" and
effective acute revascularization is possible only in
patients already in hospital, with operating facilities
alerted and coronary anatomy known beforehand.
Intracoronary lysis"6* is an interesting non-surgical
method which attempts to revascularize the myo-
cardium by reopening the obstructed vessel. It has the
advantage of combining pre-operative diagnostic
studies with therapeutic intervention, but the results
are not always convincing in terms of restoring
ventricular function and preventing myocardial
infarction"7'.
Surgical treatment in chronic heart failure is
nowadays possible only in a very limited number of
cases. In large left ventricular aneurysm with well-
delineated border zone and sufficient function of the
residual ventricle, aneurysmectomy"81 can improve
left ventricular function, decrease filling pressure and
left ventricular dimensions, and improve exercise
tolerance with elimination of heart failure caused by
ventricular dyskinesia"91.
Orthotopic cardiac transplantation with total
removal of the diseased organ represents the classic
operation for end-stage cardiomyopathy. Pioneered
experimentally in the early sixties"7' it was first
performed clinically in 1977 in an operation which
captured worldwide attention120*. After an initial
widespread application cardiac transplantation was
abandoned by most centers due to lack of suitable
donors, the high immunosuppression necessary to
keep the transplant functioning and a substantial
incidence of infections. Continuous clinical appli-
cation of this method at Stanford'2" has shown that
the operation is possible with low early mortality and
acceptable late results; improvement in myocardial
preservation techniques will widen the application of
this method. Heterotopic cardiac transplantation^11^
was designed to circumvent some of the problems
encountered in treating acute rejection episodes in
orthotopic cardiac transplants. In this operation, the
transplanted heart is attached in parallel to the
natural one and it provides a varying degree of
circulatory assistance, depending on the condition of
the natural heart. The advantages of this elegant
operation are obvious but its hemodynamic
efficiency has been questioned. Combined transplant-
ation of the heart and the lungs has been performed by
1
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the Stanford group1231 in a few selected patients as a
final solution to the problem of heart failure with
high pulmonary resistance. Although technically
simple, this operation probably entails more rejection
problems through the presence of two immuno-
logically active organs.
MECHANICAL SUPPORT OF THE FAILING HEART
In the field of acute mechanical support consider-
able advances have been made in the last decade
(Table 2).
lntra-aortic balloon pumping (IABP) was intro-
duced experimentally in 1962(24) and clinically in
1968I25). It has emerged as a safe, reliable method of
left ventricular assistance which can decrease left
ventricular failure by reducing the afterload and by
increasing diastolic pressure in the aorta, thereby
improving coronary flow. The advent of commer-
cially available pumping devices and non-
thrombogenic, reliable balloons, greatly widened the
application of IABP and it is nowadays estimated
that more than 300 000 implantations have been
performed worldwide (D. Bergman, pers. comm.).
The percutaneous balloon has eliminated the
problems of surgical balloon introduction and has
simplified the procedure; it has enabled the
cardiologist to apply the device quickly by a simple
arterial puncture.
Artificial heart research has led to the development
of assist ventricles which could be used either in a
paracorporeal position, fixed on the chest of the
patient and attached to the heart with canulae; or
intracorporeally as an abdominal left ventricular
assist device1261. These ventricles provide much more
efficient circulatory assistance than the IABP. Assist
ventricles can take over the total output of the
diseased heart and they can indeed support the
circulation in ventricular fibrillation. Separate assist
pumping of the left and right ventricle is possible1271
although careful attention has to be paid to the filling
Table 2 Mechanical circulatory support
1. Widespread clinical use:
IABP
2. Clinical trials:
assist ventricles
temporary ventricular bypass
3. Experimental stage, isolated clinical applications,
total artificial heart
implantable assist ventricles
pressures in both atria and to the output of each
ventricle. The biggest disadvantage of this method
lies in the necessity of thoracotomy for implantation
and removal of the devices, even in the paracorporeal
pumping mode. Therefore the assist ventricles have
been used only in cases of postoperative low output
syndrome, i.e. in profound heart failure occurring
after open heart surgery127 ~30). Pneumatically driven
assist ventricles, which were utilized in these clinical
trials, were hand made units, which represented the
end result of a long experimental development in the
particular center performing clinical trials. Consider-
ably simpler devices—roller pumps normally used in
open heart surgery—were also utilized for mechanical
support of the failing heart with reasonable clinical
success'3". The use of a roller pump necessitates total
heparinization of the patient which seriously limits
the application of this method; on the other hand the
use of left atrial and aortic cannulae which can be
permanently occluded and left in place precludes the
need for a second thoracotomy for the removal of the
device. All assist ventricles and bypass pumps are
'tethered' devices, the patient being attached to the
pumping console with pressure lines needed to drive
the ventricles; in the paracorporeal position blood
cannulae also penetrate the chest wall, severely
limiting the mobility of the patient. Due to numerous
difficulties (blood damage, thrombus formation,
cannulation problems, infection, bleeding) the
ventricular assist devices are used only for a few days,
to allow the recovery of the heart from a severe
postoperative low output syndrome.
Chronic mechanical support of the circulation is
possible with the use of an orthotopically implanted
total artificial heart. Although much experimental
experience has been accumulated in several centers
during the last decade, the artificial heart was used
only in two patients, and neither of them eventually
survived'321. Both clinical implants were done in a
desperate situation, with patients dying after an open
heart procedure and other methods of circulatory
assistance failing. Cardiac transplantation with
removal of the artificial heart has been performed as
soon as possible, after a suitable donor was found.
The removal of the diseased natural heart, followed
by the implantation of the mechanical heart
prosthesis is an irrevocable step which most surgeons
have been anxious to avoid. In experimental animals
mechanical circulatory support is possible in excess of
six months'331, but the problems of the long-term
biocompatibility of materials in contact with blood
have not yet been solved.
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Clinical indications and results
SURGICAL TREATMENT IN ACUTE FAILURE
In correctable lesions the guidelines for surgical
treatment are derived from the recent advances in
knowledge of the pathophysiology of acute heart
failure. The treatment must be instituted early, and it
must be curative in order to ensure the survival of the
patient. The early institution of treatment prevents
development of late complications which are related
both to heart failure and to heart changes caused by
the primary disease process. Early elimination of
heart failure prevents deterioration in the function of
the vital organs commonly seen in profound heart
failure: renal failure, coagulation disorders,
hepatic failure, pulmonary oedema and onset of
septic complications. The timing of the operation is
critical: whilst the operation should be performed
only when significant hemodynamic deterioration has
occurred, it should be early enough to enable total
restitution of cardiac function. Heart failure and
cardiac enlargement seen in acute volume or pressure
overload increase myocardial wall stress and its
oxygen consumption; they result in subendocardial
ischemia which can progress to subendocardial
necrosis, jeopardizing the results of surgical treat-
ment. The operation should be performed before
such grave deterioration occurs.
In postinfarction VSD the significant left-right
shunt with development of heart failure is an
indication for surgery per se. The operation is
performed early, regardless of the time period
between myocardial infarction and operation.
Reliable coronary angiography is necessary to show
the extent of coronary imvolvement in the non-
infarcted area; pre-operative implantation of IABP
has been particularly beneficial in this group of
patients. Mortality of less than 20% can be achieved
depending on the timing of surgery, age of the
patient, extent of the coronary disease and residual
left ventricular function. When the patient has
survived the early postoperative period, the long-term
outlook is good, although some residual shunting is
possible.
In acute valvular incompetence caused by endo-
carditis the operation is performed in the presence of
significant valvular regurgitation with heart failure,
peripheral emboli or uncontrollable infection. Oper-
ation is also considered earlier if the causative agent is
resistant or only mildly susceptible to the antibiotics.
With proper timing of surgery, the results are
comparable with elective valvular replacement but
long-term antibiotic treatment is necessary to prevent
the recurrence of infection156'.
Sudden prosthetic dysfunction—incompetence or
stenosis—in the aortic or mitral position leads to
sudden, profound heart failure and even to the death
of the patient before treatment can be instituted.
Diagnosis is usually difficult and can be made only by
excluding other sudden causes of profound heart
failure (pulmonary embolism, myocardial infarction
or acute dissection). Only a high index of suspicion
and immediate operation with minimal diagnostic
work-up can assure, the survival of the patient. The
operation has to be initiated when the patient is still
able to maintain some cardiac output to assure the
perfusion of vital organs'71.
In acute coronary insufficiency infarction can be
prevented only by immediate operation which should
start within 30-60 min after acute coronary
occlusion. A small increase in CK enzymes still
occurs but the appearance of new Q waves can
usually be prevented"41. In sudden coronary
occlusion in the course of percutaneous transluminal
angioplasty revascularization is possible without
mortality or significant morbidity.
DISAPPEARANCE OF POSTOPERATIVE HEART FAILURE
The results of open heart surgery have improved
considerably in the last years. The main cause of
death after valvular or coronary surgery in the sixties
and early seventies was the postoperative low output
syndrome, a profound biventricular heart failure
resistant to all therapeutic modalities and only
sometimes reversed by mechanical circulatory assis-
tance (IABP and assist ventricles). It is now known
that this type of heart failure is primarily caused by
ischemic damage to the heart which occurs during
aortic cross-clamping and cardiopulmonary bypass.
Contributory factors are pre-existing heart failure,
reperfusion damage after removal of the aortic cross-
clamp, low oncotic pressure and low hematocrit
during cardiopulmonary bypass, also insufficient
aortic pressure in the post-bypass period which
provokes subendocardial ischemia, especially in
patients with reduced ventricular compliance and
high filling pressure. Furthermore, volume loading
which was practised earlier usually led to iatrogenic
right ventricular failure, which very often precipitated
the development of postoperative low output
syndrome.
The prevention of this condition is—as usual—
more important than its treatment: potassium
cardioplegia has practically eliminated postoperative
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low output syndrome. Strict adherence to the
principle of rapid cardiac arrest (high potassium
concentration) and profound myocardial cooling
(ice-cold cardioplegic solution) reduces myocardial
oxygen consumption and limits myocardial energy
utilization during cross-clamping; a sufficient period
of reperfusion allows the heart to recover from the
ischemic injury and full volume and pressure load can
be taken over after a period of 15-20 min. The strict
avoidance of hypervolemia, an adequate hematocrit
and sufficient arterial perfusion pressure can also
prevent the development of this type of heart failure.
When the signs of left ventricular failure appear.
IABP is used much more aggressively; arrhythmias
are strictly controlled and physiological cardiac
pacing (AV synchronous) is used instead of simple
ventricular stimulation, when the optimal heart rate
cannot be maintained spontaneously.
SURGICAL TREATMENT OF CHRONIC HEART FAILURE
Left ventricular aneurysmectomy is an established
procedure with known indications. It is not the
purpose of this communication to discuss this
procedure; however, it can be stated that the early
mortality of less than 5% is achieved in patients with
suitable indications"31; that the procedure improves
left ventricular function, decreases filling pressure and
increases patients work capacity; there is no definite
proof that it also increases patients' survival, due to
the lack of truly randomized studies.
Cardiac transplantation (for the purpose of this
discussion both ortho- and heterotopic procedures are
grouped together) has well defined selection cri-
teria'34'. The procedure should be performed in
patients with terminal cardiac disease, with calculated
survival of less than 12 months. Patients should be
less than 55 years of age, pulmonary vascular
resistance should be below 8 U and patients should be
able to comply with the complex medical regimen of
chronic immunosuppression. The following diseases
represent a contraindication to transplantation:
insulin-dependent diabetes mellitus, presence of any
degree of infection, recent pulmonary infarction,
peptic ulcer, substantial cerebrovascular or peripheral
vascular disease, any degree of chronic addiction or
other significant diseases which might shorten the
survival of the patient. With strict adherence to these
criteria, a survival rate of 70% at one year after
transplantation can be achieved'341. Although late
attrition remains a problem, the largest mortality is
encountered in the first three months after transplant-
ation. The results are not uniform: great variability in
Table 3 Cardiac transplantution: pros and co/i.s
Advantages
Cardiac function restored
Long-term results acceptable
Better immunosuppression
Diagnostics of rejection
Contraindications established
Only available treatment
Disadvantages
Lack of donors
Heart preservation deficient
Natural course of cardiopathy uncertain
Late attrition rate
High cost
Social-economic objections
one year survival rates is encountered among
difference centers ranging from 72 38°,,,(34-33).
Cardiac transplantation does indeed provide an
almost complete restoration of cardiac function with
acceptable long-term results which are due to an
improved regimen (Cyclosponn A) and better
recognition of rejection by serial biopsy; furthermore
the procedure has now a well established list of
contraindications (Table 3). Still, most centers have
been reluctant to adopt cardiac transplantation after
the initial failures. The most common arguments
against cardiac transplantation are the relative
shortage of donors and inadequate methods for heart
preservation and storage. Furthermore, the pro-
cedure still has a substantial late attrition rate and it
is performed in a disease—cardiomyopathy— with an
unpredictable natural course, where late recoveries
are possible. The intensive late surveillance and
treatment necessary make this therapeutic modality a
very costly one; it is also applicable to only a few
patients and social-economic reasons have been
quoted against cardiac transplantation, i.e. dispro-
portionate allocation of limited means to a very few
patients.
MECHANICAL CIRCULATORY SUPPORT
IABP has gained widespread clinical acceptance in
the last decade. It gives the best results (Table 4) when
used for temporary stabilization of the patient, either
to perform a diagnostic evaluation (coronary
angiography) or prior to surgery (postinfarction
VSD. unstable angina pectoris, severe left main
coronary stenosis with obstruction of the right
coronary artery, etc.). The results are mediocre when
the device is applied in postoperate heart failure after
valvular surgery, where a success rate of
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Table 4 IABP clinical results
High survival:
perioperative use in coronary grafting unstable angina
(before surgery)
Moderate success:
heart failure after valvular surgery
Poor results:
congenital heart disease (postoperatively)
Cardiomyopathy and myocarditis
Cardiogenic shock
Toxic and septic heart failure
IABP and transplantation
approximately 50?n has to be accepted13637'. IABP
gives very poor results in postoperative heart failure
after correction of congenital heart malformations, in
cardiomyopathy and myocarditis as well as in
cardiogenic shock when not combined with cardiac
surgery. It also fails in toxic and septic heart failure.
Recent experience demonstrates that the use of IABP
followed by cardiac transplantation138' has a poor
long-term prognosis; from the beginning this method
was not accepted by other transplantation centers.
IABP provides reliable hemodynamic benefit with a
low incidence of early and late complications; blood
damage remains minimal and the mechanical
assistance can be performed for days and even weeks.
Although the overall use of IABP is in decline in
postoperative heart failure, it is used more
aggressively by cardiologists for pre-operative
stabilization of patients.
Assist ventricles have been used by numerous
groups in the recent years, almost exclusively in cases
with profound heart failure after open heart surgery.
By adherence to a strict list of criteria (all surgical
problems solved, blood pressure below 80 mm Hg,
left atrial pressure above 20 mm Hg, full
catecholamine support, IABP implanted, pH and
electrolytes normalized and all arrhythmias
controlled) the results were poor: only a few patients
are long-term survivors, and the program of
mechanical ventricular assistance has been suspended
in many centers which previously worked in this field.
Again, the disappearance of postoperative low output
syndrome has eliminated the major area of appli-
cation for this type of circulatory support; it remains
to be seen if a higher success rate can be obtained in
patients with profound cardiogenic shock after
myocardial infarction, when the device is employed
after acute revascularization. The total artificial heart
is still in an experimental stage and all clinical
applications were unsuccessful. It is questionable if
the present artificial heart should be offered to
patients in endstage cardiomyopathy and if patients
will be able to accept a 'tethered' device with a limited
life span, which will furthermore severely limit their
mobility and reduce their quality of life.
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